Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks, and under the breasts.

The hidradenitis suppurativa drugs in development report provides an overview of the hidradenitis suppurativa pipeline landscape. The report provides comprehensive information on the therapeutics under development for hidradenitis suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for hidradenitis suppurativa and features dormant and discontinued projects.

What are the targets of the hidradenitis suppurativa pipeline drugs market?

The targets of the hidradenitis suppurativa pipeline drugs market are Tumor Necrosis Factor, Complement C5, Interleukin 1 Alpha, Interleukin 1 Receptor Like 2, Interleukin 17A, Interleukin 23 Subunit Alpha, Tyrosine Protein Kinase JAK1, Interleukin 1 Receptor Associated Kinase 4, Phosphodiesterase 4, Tumor Necrosis Factor Receptor Superfamily Member 5, and others.

Hidradenitis suppurativa pipeline drugs market, by targets

Hidradenitis suppurativa pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the hidradenitis suppurativa pipeline drugs market?

The mechanisms of action of the hidradenitis suppurativa pipeline drugs market are Tumor Necrosis Factor Inhibitor, Complement C5 Inhibitor, Interleukin 1 Alpha Inhibitor, Interleukin 1 Receptor Like 2 Antagonist, Interleukin 17A Inhibitor, Interleukin 23 Subunit Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 1 Receptor Associated Kinase 4 Inhibitor, Phosphodiesterase 4 Inhibitor, Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist, and others.

Hidradenitis suppurativa pipeline drugs market, by mechanisms of action

Hidradenitis suppurativa pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the hidradenitis suppurativa pipeline drugs market?

The routes of administration in the hidradenitis suppurativa pipeline drugs market are subcutaneous, intravenous, oral, and topical.

Hidradenitis suppurativa pipeline drugs market, by routes of administration

Hidradenitis suppurativa pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

For more routes of administration insights, download a free report sample

The molecule types in the hidradenitis suppurativa pipeline drugs market are monoclonal antibody, small molecule, fusion protein, monoclonal antibody conjugated, and synthetic peptide.

Hidradenitis suppurativa pipeline drugs market, by molecule types

Hidradenitis suppurativa pipeline drugs market, by molecule types

For more molecule types insights, download a free report sample

Which are the key companies in the hidradenitis suppurativa pipeline drugs market?

Some of the key companies in the hidradenitis suppurativa pipeline drugs market are Novartis AG, AbbVie Inc, Acelyrin Inc, Aclaris Therapeutics Inc, Afecta Pharmaceuticals Inc, Alvotech ehf, Amgen Inc, AnaptysBio Inc, AstraZeneca Plc, Attillaps Holdings Inc, Azora Therapeutics Australia Pty Ltd, BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, ChemoCentryx Inc, and CSL Ltd.

Hidradenitis suppurativa pipeline drugs market, by key companies

Hidradenitis suppurativa pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Tumor Necrosis Factor, Complement C5, Interleukin 1 Alpha, Interleukin 1 Receptor Like 2, Interleukin 17A, Interleukin 23 Subunit Alpha, Tyrosine Protein Kinase JAK1, Interleukin 1 Receptor Associated Kinase 4, Phosphodiesterase 4, and Tumor Necrosis Factor Receptor Superfamily Member 5
Mechanisms of Action Tumor Necrosis Factor Inhibitor, Complement C5 Inhibitor, Interleukin 1 Alpha Inhibitor, Interleukin 1 Receptor Like 2 Antagonist, Interleukin 17A Inhibitor, Interleukin 23 Subunit Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 1 Receptor Associated Kinase 4 Inhibitor, Phosphodiesterase 4 Inhibitor, and Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist
Routes of Administration Subcutaneous, Intravenous, Oral, and Topical
Molecule Types Monoclonal Antibody, Small Molecule, Fusion Protein, Monoclonal Antibody Conjugated, and Synthetic Peptide
Key Companies AbbVie Inc, Acelyrin Inc, Aclaris Therapeutics Inc, Afecta Pharmaceuticals Inc, Alvotech ehf, Amgen Inc, AnaptysBio Inc, AstraZeneca Plc, Attillaps Holdings Inc, Azora Therapeutics Australia Pty Ltd, BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, ChemoCentryx Inc, and CSL Ltd

This report provides:

  • A snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
  • Reviews of pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

AbbVie Inc
Acelyrin Inc
Aclaris Therapeutics Inc
Afecta Pharmaceuticals Inc
Alvotech ehf
Amgen Inc
AnaptysBio Inc
AstraZeneca Plc
Attillaps Holdings Inc
Azora Therapeutics Australia Pty Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
ChemoCentryx Inc
CSL Ltd
Eli Lilly and Co
Ichnos Sciences Inc
Immunwork Inc
Incyte Corp
InflaRx NV
Inmagene Biopharmaceuticals Ltd
Innovation Pharmaceuticals Inc
Johnson & Johnson
Jubilant Therapeutics Inc
Kiniksa Pharmaceuticals Ltd
Kymera Therapeutics, Inc
Lytix Biopharma AS
NeuClone Pty Ltd
NovaRock Biotherapeutics Inc
Novartis AG
Pfizer Inc
Pharmapraxis
Phoenicis Therapeutics Inc
Regranion LLC
Rigel Pharmaceuticals Inc
Staidson (Beijing) Biopharmaceuticals Co Ltd
UCB SA
Union Therapeutics AS
VYNE Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hidradenitis Suppurativa – Overview

Hidradenitis Suppurativa – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hidradenitis Suppurativa – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hidradenitis Suppurativa – Companies Involved in Therapeutics Development

Hidradenitis Suppurativa – Drug Profiles

Hidradenitis Suppurativa – Dormant Projects

Hidradenitis Suppurativa – Discontinued Products

Hidradenitis Suppurativa – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Hidradenitis Suppurativa, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hidradenitis Suppurativa – Pipeline by AbbVie Inc, 2022

Hidradenitis Suppurativa – Pipeline by Acelyrin Inc, 2022

Hidradenitis Suppurativa – Pipeline by Aclaris Therapeutics Inc, 2022

Hidradenitis Suppurativa – Pipeline by Afecta Pharmaceuticals Inc, 2022

Hidradenitis Suppurativa – Pipeline by Alvotech ehf, 2022

Hidradenitis Suppurativa – Pipeline by Amgen Inc, 2022

Hidradenitis Suppurativa – Pipeline by AnaptysBio Inc, 2022

Hidradenitis Suppurativa – Pipeline by AstraZeneca Plc, 2022

Hidradenitis Suppurativa – Pipeline by Attillaps Holdings Inc, 2022

Hidradenitis Suppurativa – Pipeline by Azora Therapeutics Australia Pty Ltd, 2022

Hidradenitis Suppurativa – Pipeline by BioXpress Therapeutics SA, 2022

Hidradenitis Suppurativa – Pipeline by Boehringer Ingelheim International GmbH, 2022

Hidradenitis Suppurativa – Pipeline by ChemoCentryx Inc, 2022

Hidradenitis Suppurativa – Pipeline by CSL Ltd, 2022

Hidradenitis Suppurativa – Pipeline by Eli Lilly and Co, 2022

Hidradenitis Suppurativa – Pipeline by Ichnos Sciences Inc, 2022

Hidradenitis Suppurativa – Pipeline by Immunwork Inc, 2022

Hidradenitis Suppurativa – Pipeline by Incyte Corp, 2022

Hidradenitis Suppurativa – Pipeline by InflaRx NV, 2022

Hidradenitis Suppurativa – Pipeline by Inmagene Biopharmaceuticals Ltd, 2022

Hidradenitis Suppurativa – Pipeline by Innovation Pharmaceuticals Inc, 2022

Hidradenitis Suppurativa – Pipeline by Johnson & Johnson, 2022

Hidradenitis Suppurativa – Pipeline by Jubilant Therapeutics Inc, 2022

Hidradenitis Suppurativa – Pipeline by Kiniksa Pharmaceuticals Ltd, 2022

Hidradenitis Suppurativa – Pipeline by Kymera Therapeutics, Inc, 2022

Hidradenitis Suppurativa – Pipeline by Lytix Biopharma AS, 2022

Hidradenitis Suppurativa – Pipeline by NeuClone Pty Ltd, 2022

Hidradenitis Suppurativa – Pipeline by NovaRock Biotherapeutics Inc, 2022

Hidradenitis Suppurativa – Pipeline by Novartis AG, 2022

Hidradenitis Suppurativa – Pipeline by Pfizer Inc, 2022

Hidradenitis Suppurativa – Pipeline by Pharmapraxis, 2022

Hidradenitis Suppurativa – Pipeline by Phoenicis Therapeutics Inc, 2022

Hidradenitis Suppurativa – Pipeline by Regranion LLC, 2022

Hidradenitis Suppurativa – Pipeline by Rigel Pharmaceuticals Inc, 2022

Hidradenitis Suppurativa – Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, 2022

Hidradenitis Suppurativa – Pipeline by UCB SA, 2022

Hidradenitis Suppurativa – Pipeline by Union Therapeutics AS, 2022

Hidradenitis Suppurativa – Pipeline by VYNE Therapeutics Inc, 2022

Hidradenitis Suppurativa – Dormant Projects, 2022

Hidradenitis Suppurativa – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Hidradenitis Suppurativa, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.